Lakefront Biotherapeutics (LKFT) Total Current Liabilities (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Total Current Liabilities for 13 consecutive years, with $117.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 74.43% year-over-year to $117.6 million; the TTM figure through Mar 2026 stood at $117.6 million (down 74.43% YoY), while the FY2025 annual figure was $177.9 million, down 50.31% from the prior year.
• Total Current Liabilities slipped to $117.6 million in Q1 2026 per LKFT's latest filing, from $177.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $631.8 million in Q1 2022 and bottomed at $117.6 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $420.7 million across 5 years, with a median of $456.1 million in 2025.
• Annual changes were most pronounced in 2025 — Total Current Liabilities grew 11.1% — and 2026, when it plunged 74.43%.
• Lakefront Biotherapeutics' Total Current Liabilities stood at $533.1 million in 2022, then dropped by 13.58% to $460.7 million in 2023, then declined by 22.28% to $358.1 million in 2024, then tumbled by 50.31% to $177.9 million in 2025, then plunged by 33.93% to $117.6 million in 2026.
• Business Quant data shows LKFT's Total Current Liabilities at $117.6 million in Q1 2026, $177.9 million in Q4 2025, and $428.5 million in Q3 2025.